Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: Role of different tropism testing results and of concomitant treatments

AIDS Research and Human Retroviruses

Volumn 30, Issue 1, 2014, Pages 17-24

  Rossetti, Barbara ^a   Bianco, Claudia ^a   Bellazzi, Lara Ines ^b   Bruzzone, Bianca ^c   Colao, Grazia ^d   Corsi, Paola ^d   Monno, Laura ^e   Pagano, Gabriella ^c   Paolucci, Stefania ^b   Punzi, Grazia ^f   Setti, Maurizio ^c   Zazzi, Maurizio ^a   De Luca, Andrea ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; MARAVIROC; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOHEXANE DERIVATIVE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT; TRIAZOLE DERIVATIVE;

ADULT; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL; VIRAL TROPISM; VIRUS LOAD; BLOOD; DRUG EFFECTS; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MORTALITY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CCR5 RECEPTOR ANTAGONISTS; CD4 LYMPHOCYTE COUNT; CYCLOHEXANES; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; RNA, VIRAL; SURVIVAL; TRIAZOLES; VIRAL LOAD; VIRAL TROPISM;

EID: 84891778812     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0235     Document Type: Article

References (31)

1. Clapham PR and McKnight A: Cell surface receptors, virus entry and tropism of primate lentiviruses. J Gen Virol 2002;83:1809-1829.
2. Moore JP, Kitchen SG, Pugach P, et al.: The CCR5 and CXCR4 co-receptors central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004;20:111-126.
3. Gulick RM, Lalezari J, Goodrich J, et al.: Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-1441.
4. European Medicines Agency (EMA): www.ema.europa.eu/humandocs/./celsentri. ht. September 18, 2007.
5. US Food and Drug Administration (FDA): www.fda.gov/cder/foi/label/2007/ 022128lbl.pdf. June 8, 2007.
6. AIDS info. Adult and Adolescent Guidelines: www.aidsinfo .nih.gov/Guidelines. Accessed January 14, 2012.
7. Vandekerckhove, Verhofstede C, Demecheleer E, et al.: Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment. J Antimicrob Chemother 2011;66:265-272.
8. Chueca N, Garrido C, Alvarez M, et al.: Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. J Med Virol 2009;81:763-767.
9. Rose JD, Rhea AM, Weber J, et al.: Current tests to evaluate HIV-1 co-receptor tropism. Curr Opin HIV AIDS 2009;4(2): 136-142.
10. Reeves JD, Coakley E, Petropoulos CJ, et al.: An enhancedsensitivity Trofile HIV co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: A review of analytical and clinical studies. J Viral Entry 2009;3:94-102.
11. Trinh L, Han D, Huang W, et al.: Technical validation of an enhanced sensitivity Trofle HIV co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5. Antivir Ther 2008;13(Suppl 3):A128.
12. Vandekerckhove LP, Wensing AM, et al; European Consensus Group on clinical management of tropism testing. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011;11(5):394-407.
13. Ruiz-Mateos E, González-Serna A, Genebat M, et al.: Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: Frequency of subjects with virological response and associated factors. Antimicrob Agents Chemother 2011;55(10):4664-4669.
14. Reuter S, Braken P, Jensen B, et al.: Maraviroc in treatmentexperienced patients with HIV-1 infection experience from routine clinical practice. Eur J Med Res 2010;15(6): 231-237.
15. De Luca A, Meini G, Rossetti B, et al.: HIV-1 co-receptor tropism evolution in näve patients undergoing successful ART: Concordance of DNA vs RNA and triplicate vs singlicate sequencing. 10th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, Barcelona, Spain, March 28-30, 2012. Abstract O17.
16. Pulido I, Machmach K, Romero-Sánchez MC, et al.: T-cell changes after a short-term exposure to maraviroc in HIVinfected patients are related to antiviral activity. J Infect 2012;64(4):417-423.
17. Schuitemaker H, Koot M, Kootstra NA, et al.: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992;66:1354-1360.
18. Connor RI, Sheridan KE, Ceradini D, et al.: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-628.
19. Fenyo EM, Morfeldt-Manson L, Chiodi F, et al.: Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol 1988;62:4414-4419.
20. Koot M, Keet IP, Vos AH, et al.: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4 cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-688.
21. Koot M, van Leeuwen R, de Goede REY, et al.: Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 1999;179:254-258.
22. Richman DD and Bozzette SA: The impact of the syncytiuminducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-974.
23. Michael NL, Chang G, Louie LG, et al.: The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997;3:338-340.
24. McGovern RA, Thielen A, Mo T, et al.: Population-based V3 genotypic tropism assay: A retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010;24(16):2517-2525.
25. Swenson L, Dong W, Mo T, et al.: Use of cellular HIV DNA to predict virologic response to maraviroc: Performance of population-based and deep sequencing. Clin Infect Dis 2013 56:1569-1576.
26. Heredia A, Gilliam B, De Vico A, et al.: CCR5 density levels on primary CD4 T cells impact the replication and enfuvirtide susceptibility of R5 HIV-1. AIDS 2007;21(10):1317-1322.
27. Melby T, Despirito M, Demasi R, et al.: HIV-1 co-receptor use in triple-class treatment-experienced patients: Baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 2006;194(2):238-246.
28. Svicher V, Aquaro S, D'Arrigo R, et al.: Specific enfuvirtideassociated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4( + ) cell count, despite virological failure. J Infect Dis 2008;197(10):1408-1418.
29. Melby TE, Despirito M, Demasi RA, et al.: Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy. AIDS 2007;21(18):2537-2539.
30. Westby M, et al.: Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006;80:4909-4920.
31. Prosperi MCF, Bracciale L, Fabbiani M, et al.: Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology 2010;7:56.